



Mab to p53

Clone Determination	Bp53-11
Category	Mouse monoclonal
Immunoglobulin Class	IgG2a
Purification/Form	Hybridoma culture supernatant
Antigen	Recombinant human p53 (transcription domain within the NH ₂ terminus)
Description/Specificity	Excellent marker for wild-type and mutant forms of human p53 antigen. Epitope recognized by Bp53.11: ²⁰ SDLWKLLPENNV ³¹ . The antibody stains positively approx. 60 % of investigated carcinoma of lung, breast, colon, stomach, esophagus, pancreas, urinary bladder and testis, head and neck tumors; T-cell leukaemia, non-Hodgkin-Lymphoma, melanoma, sarcoma.
Antigen Recognized in Species (tested so far)	Human
Reactivities on Cultured Cell Lines (tested so far)	Hela, MCF-7
Application	<ul style="list-style-type: none">- Suitable for immunohistochemistry with frozen and paraffin-embedded tissue, cytological material- Immunoblotting- Immunoprecipitation- ELISA
Working Dilution	Ready-to-use for immunohistochemical application
Pretreatment	No pretreatment required. Do not apply proteases!
Incubation Time	1 h at 37°C, extended with paraffin sections (overnight at 2-8°C). APAAP, PAP or streptavidin/ biotin method or application of signal amplification system is strongly recommended.
Quantity	5 mL (contains 0.09% sodium azide)

References

- Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. *Int J Cancer* **46**, 839-844 (1990)
- Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP: Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. *J Pathol* **169**, 27-34 (1993)
- Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR: Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. *Br J Cancer* **60**, 26-31 (1994)
- Petersen G, Song D, Hügler-Dörr B, Oldenburg I, Bautz EKF: Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. *Mol Gen Genet* **249**, 425-431 (1995)
- Stephen CW, Helminen P, Lane DP: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. *J Mol Biol* **248**, 58-78 (1995)
- Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conrad C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX: Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. *Cancer Res* **58**, 5-13 (1998)
- Homann N, Nees M, Conrad C, Dietz A, Weidauer H, Maier H, Bosch FX: Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. *Clin Cancer Res* **7**, 290-296 (2001)
- Ohtake S, Cheng J, Ida H, Suzuki M, Ohshiro K, Zhang W, Saku T: Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by p53 immunohistochemistry. *J Oral Pathol Med* **31**, 590-597 (2002)
- Zarka TA, Han AC, Edelson MI, Rosenblum NG: Expression of cadherins, p53, and BCL2 in small cell carcinomas of the cervix: Potential tumor suppressor role for N-cadherin. *Int J Gynecol Cancer* **13**, 240-243 (2003)

Cat. No. 65139